Crossmark

Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis

Crossref DOI link: https://doi.org/10.1186/s13601-020-00330-1

Published Online: 2020-06-26

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Heffler, Enrico http://orcid.org/0000-0002-0492-5663
Saccheri, Fabiana

Bartezaghi, Marta

Canonica, Giorgio Walter
License Information

Text and Data Mining valid from 2020-06-26

Version of Record valid from 2020-06-26
More Information

Article History

Received: 6 December 2019

Accepted: 11 June 2020

First Online: 26 June 2020

Ethics approval and consent to participate

: PROXIMA was conducted according to the ethical principles of the Declaration of Helsinki and the Italian Medicines Agency (AIFA) Guideline for the classification and management of observational studies on drugs [36–38]. All patients provided informed consent before participating in the study.

: Enrico Heffler is an advisory board member and speaker for Novartis, AstraZeneca, Sanofi-Genzyme, GSK, Teva, Circassia, and Nestlè Purina. Fabiana Saccheri and Marta Bartezaghi are employees of Novartis. Giorgio Walter Canonica has received research grants, as well as lecture or advisory board fees, from A. Menarini, Alk-Abello, Allergy Therapeutics, Anallergo, AstraZeneca, MedImmune, Boehringer Ingelheim, Chiesi Farmaceutici, Circassia, Danone, Faes, Genentech, Guidotti-Malesci, GlaxoSmithKline, Hal Allergy, Merck, MSD, Mundipharma, Novartis, Orion, Sanofi-Aventis, Sanofi, Genzyme/Regeneron, Stallergenes, UCB Pharma, Uriach Pharma, Teva, Thermo Fisher, and Valeas.

Document is current

Any future updates will be listed below